Table 1 Clinical characteristics of patients with MCTD
From: Association study between immune-related miRNAs and mixed connective tissue disease
MCTD | ||||
|---|---|---|---|---|
Clinical parameters | N* | Mean values ± SD or n** (%) | ||
Demographic characteristics | Age | 100 | 43.43 ± 13.77471 | |
Gender (n = female) | 100 | 84 (84%) | ||
Disease activity | Disease duration [months] | 100 | 148.2 ± 272.6612 | |
Damage index | 100 | 9.79 ± 13.547 | ||
The course of disease | Single phase | 100 | 12 (12%) | |
Multiphase | 28 (28%) | |||
Progressive | 60 (60%) | |||
Autoantibody profile | Anti-U1 RNP | 100 | 99 (99%) | |
Anti-U1 RNP | 70 | 100 | 75 (75%) | |
A | 100 | 83 (83%) | ||
C | 100 | 79 (79%) | ||
Anti-CCP | 71 | 3 (4.22%) | ||
Anti-ANA | 99 | 98 (98.98%) | ||
Anti-SmB | 100 | 31 (31%) | ||
Anti-SmD | 100 | 6 (6%) | ||
Anti-Ro 60 | 100 | 10 (10%) | ||
Anti-Ro 52 | 100 | 24 (24%) | ||
Anti-La | 100 | 2 (2%) | ||
Anti-Rib P | 100 | 3 (3%) | ||
Anti-PCNA | 100 | 1 (1%) | ||
Anti-CENP B | 100 | 0 | ||
Anti-Scl-70 | 100 | 2 (2%) | ||
Anti-Jo-1 | 100 | 1 (1%) | ||
Anti-His | 100 | 15 (15%) | ||
Anti-DNA | 100 | 13 (13%) | ||
RF | 98 | 36 (36.73%) | ||
Clinical manifestation | SLE-like skin lesions | 100 | 71 (71%) | |
Ocular lesions | 99 | 60 (60.60%) | ||
Cardiomyopathy | 100 | 4 (4%) | ||
Dysphagia | 100 | 22 (22%) | ||
Deforming or erosive arthritis | 100 | 12 (13%) | ||
Poikiloderma | 100 | 31 (31%) | ||
Raynaud syndrome | 100 | 97 (97%) | ||
Sjögren’s syndrome | 69 | 22 (31.88%) | ||
Swollen fingers or hands | 100 | 92 (92%) | ||
Polyarthritis | 100 | 94 (94%) | ||
Lymphadenopathy | 100 | 26 (26%) | ||
Facial erythema | 100 | 43 (43%) | ||
Pericarditis/pleuritis | 100 | 16 (16%) | ||
Leukopenia/thrombocytopenia | 100 | 65 (65%) | ||
Scleroderma | 100 | 34 (34%) | ||
Pulmonary fibrosis | 100 | 31 (31%) | ||
Esophageal disorders | 100 | 23 (23%) | ||
Myopathy | 100 | 66 (66%) | ||